ATE152915T1 - Immuntherapeutische vektorkonstrukte gegen krebs - Google Patents

Immuntherapeutische vektorkonstrukte gegen krebs

Info

Publication number
ATE152915T1
ATE152915T1 AT93900751T AT93900751T ATE152915T1 AT E152915 T1 ATE152915 T1 AT E152915T1 AT 93900751 T AT93900751 T AT 93900751T AT 93900751 T AT93900751 T AT 93900751T AT E152915 T1 ATE152915 T1 AT E152915T1
Authority
AT
Austria
Prior art keywords
altered
altered cellular
expression
vector constructs
recombinant virus
Prior art date
Application number
AT93900751T
Other languages
English (en)
Inventor
Sunil Chada
Mordechai Bodner
Douglas J Jolly
Jack R Barber
Cataline Dejesus-Harkleroad
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Application granted granted Critical
Publication of ATE152915T1 publication Critical patent/ATE152915T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT93900751T 1991-11-29 1992-11-30 Immuntherapeutische vektorkonstrukte gegen krebs ATE152915T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80032891A 1991-11-29 1991-11-29

Publications (1)

Publication Number Publication Date
ATE152915T1 true ATE152915T1 (de) 1997-05-15

Family

ID=25178122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900751T ATE152915T1 (de) 1991-11-29 1992-11-30 Immuntherapeutische vektorkonstrukte gegen krebs

Country Status (10)

Country Link
US (1) US5693522A (de)
EP (1) EP0615453B1 (de)
JP (1) JPH07501942A (de)
AT (1) ATE152915T1 (de)
AU (1) AU671971B2 (de)
CA (1) CA2117303C (de)
DE (1) DE69219787T2 (de)
FI (1) FI942503A (de)
NO (1) NO941986L (de)
WO (1) WO1993010814A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2140624C (en) * 1992-07-22 2001-05-01 Arnold J. Levine P53 vaccine
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
US6953573B1 (en) * 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5629192A (en) * 1994-02-04 1997-05-13 The United States Of America As Represented By The Department Of Health And Human Services ETS1 gene: a human tumor suppressor gene
KR970702915A (ko) * 1994-04-29 1997-06-10 린다 버겐 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
JP4125784B2 (ja) * 1995-10-20 2008-07-30 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 抗原提示細胞により仲介される免疫応答を高めるための組成物および方法
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US6365151B1 (en) * 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
EP1997900A3 (de) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Rekombinante Vektoren auf Alphavirus-Basis mit reduzierter Hemmung der zellulären Makromolekularsynthese
JP2001500738A (ja) * 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU747577B2 (en) * 1997-01-30 2002-05-16 Novartis Vaccines And Diagnostics, Inc. Use of microparticles with adsorbed antigen to stimulate immune responses
WO1998051369A1 (en) 1997-05-13 1998-11-19 Edwards Stuart D Global medical treatment method and apparatus
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
JP2002527467A (ja) 1998-10-20 2002-08-27 サルバトーレ・アルバーニ 抗原特異的ｔ細胞の単離、定量、特徴づけおよび調節方法
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
WO2001016167A2 (en) * 1999-09-01 2001-03-08 The Johns Hopkins University Beta-catenin, tcf-4, and apc interact to prevent cancer
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002226030A1 (en) * 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
AU2003294220A1 (en) 2002-09-17 2004-04-23 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CN101355960A (zh) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP4088772A1 (de) * 2008-01-28 2022-11-16 Implantica Patent Ltd. Drainagevorrichtung
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
RU2718663C2 (ru) 2016-01-19 2020-04-13 Пфайзер Инк. Противораковые вакцины

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4965196A (en) * 1983-01-19 1990-10-23 Genentech, Inc. Polycistronic expression vector construction
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
ATE126534T1 (de) * 1987-05-29 1995-09-15 Dana Farber Cancer Inst Inc Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung.
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
EP0378576B1 (de) * 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
WO1990002806A1 (en) * 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
CA2425745C (en) * 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
NO941986L (no) 1994-07-27
FI942503A0 (fi) 1994-05-27
CA2117303C (en) 2000-10-17
NO941986D0 (no) 1994-05-27
DE69219787T2 (de) 1997-08-28
JPH07501942A (ja) 1995-03-02
AU3229793A (en) 1993-06-28
EP0615453A1 (de) 1994-09-21
EP0615453B1 (de) 1997-05-14
DE69219787D1 (de) 1997-06-19
WO1993010814A1 (en) 1993-06-10
FI942503A (fi) 1994-05-27
US5693522A (en) 1997-12-02
AU671971B2 (en) 1996-09-19
CA2117303A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
ATE152915T1 (de) Immuntherapeutische vektorkonstrukte gegen krebs
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
DE68929122D1 (de) Rekombinante Retroviren
CY1113689T1 (el) Εξασθενημενοι ιοι αρνητικου κλωνου με αλλοιωμενη δραστικοτητα ανταγωνισμου ιντερφερονης για χρηση ως εμβολια και φαρμακευτικα προϊοντα
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
DE59410380D1 (de) Endosomolytisch wirksame partikel
DK11789D0 (da) Rekombinante vaccinia-vira
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
DK0588578T3 (da) Immunogener
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
DE69322872T2 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
RU94028669A (ru) Векторная конструкция, рекомбинантные вирусы, рекомбинантный ретровирус, клетки-мишени, композиция, применение композиции
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
DK0382075T3 (da) Phenylhydrazoner af beta-jononer, fremstilling heraf og heraf fremstillede lægemidler og kosmetika

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee